title: EGFR exon mutation distribution and outcome in non-small-cell lung cancer: a Portuguese retrospective study.
abstract: Epidermal growth factor receptor (EGFR) mutations play a predictive role in advanced stages of non-small-cell lung cancer (NSCLC) patients. We conducted this study in order to assess EGFR status in a Portuguese population and its role in NSCLC patients' outcomes. Patients were submitted to EGFR assessment by high-resolution melting and/or direct sequencing. Kaplan-Meier curve was used to assess overall survival and progression-free survival (PFS). Two hundred forty eight out of 322 participants were assessed for EGFR status. Forty-two patients (16.9 %) presented EGFR-mutated status: one patient (2.4 %) presented exon 18; 21 patients (50 %), exon 19; one patient (2.4 %), exon 20; and 18 patients (45.2 %), exon 21 mutations, p < 0.001. PFS was not assessed (n.a.) for patient with exon 18 mutation, and for the other patients with mutations, it was 7 months (3.96-10.03) (exon 19), <1 month (exon 20), and 7 months (0-14.2) (exon 21) (p = 0.027). Overall survival (OS) was 11 months (exon 18), 11 months (1-18) (exon 19), 1 month (exon 20), and 7.5 months (2-70) (exon 21) (p = n.a). This study suggests that the EGFR mutation is herein observed in a higher proportion than expected for a Caucasian population, and OS is a little less than that published in the literature.
authors: Department of Medical Oncology, Portuguese Oncology Institute, Rua Dr António Bernardino de Almeida, 4200-079 Porto, Portugal. ramondemello@gmail.com
authors: Ramon Andrade
authors: RA
authors: de Mello
authors: Filipa Soares
authors: FS
authors: Pires
authors: Dânia Sofia
authors: DS
authors: Marques
authors: Júlio
authors: J
authors: Oliveira
authors: Ana
authors: A
authors: Rodrigues
authors: Marta
authors: M
authors: Soares
authors: Isabel
authors: I
authors: Azevedo
authors: Ana
authors: A
authors: Peixoto
authors: Catarina
authors: C
authors: Santos
authors: Carla
authors: C
authors: Pinto
authors: Venceslau
authors: V
authors: Hespanhol
authors: Manuel R
authors: MR
authors: Teixeira
authors: Teresina
authors: T
authors: Amaro
authors: Henrique
authors: H
authors: Queiroga
authors: António
authors: A
authors: Araújo
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality; D066246:ErbB Receptors / Q000235:genetics*; D005091:Exons / Q000235:genetics*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009154:Mutation / Q000235:genetics*; D009367:Neoplasm Staging; D011174:Portugal; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate
chemical_list: C512478:EGFR protein, human; D066246:ErbB Receptors